Treatment of retroperitoneal fibrosis with rituximab, cyclophosphamide and dexamethasone, followed by rituximab and dexamethasone maintenance, achieved disappearance of pathological PET accumulation of FDG and regression of fibrotic masses after 4 months of therapy and the patient is still in complete remission after 3 years. A case report and iteraure review.

Česká verzia

Authors: A. Čermák ¹; J. Foukal ²; Z. Řehák ³; Z. Adam ⁴; M. Keřkovský ²; L. Hruška ⁵; M. Borský ⁶; M. Doubek ⁶; J. Vlažný ⁷; Z. Pavlovský ⁷; Z. Chovancová ⁸; I. Boichuk ⁴; M. Štork ⁴; L. Pour ⁴; R. Koukalová ³; M. Tomíška ³; Z. Král ³
Authors place of work: Urologická klinika LF MU a FN Brno ¹; Klinika radiologie a nukleární medicíny LF MU a FN Brno ²; Oddělení nukleární medicíny, MOU Brno ³; Interní hematologická a onkologická klinika LF MU a FN Brno ⁴; Oddělení zobrazovacích metod, SurGal Clinic s. r. o., Brno ⁵; Centrum molekulární bio logie a genetiky, Interní hematologická a onkologická klinika, LF MU a FN Brno ⁶; Ústav patologické anatomie LF MU a FN Brno ⁷; Ústav klinické imunologie a alergologie LF MU a FN u sv. Anny v Brně ⁸
Published in the journal: Klin Onkol 2024; 38(5): 354-369
Category: Case Reports
doi: https://doi.org/10.48095/ccko2024354

Summary

Background: Idiopathic retroperitoneal fibrosis is characterized by the development of inflammatory infiltrates with marked fibrosis along the large retroperitoneal vessels. Rituximab in combination with glucocorticoids constitute an effective therapy, but the responses are not long-lasting. In other similar situations, addition of cyclophosphamide to the combination achieved longer and deeper responses. This was the reason to use the triple combination in this case. Case: A 56-year-old man came with four weeks lasting abdominal pain with CT finding of retroperitoneal fibrosis with unilateral ureteral occlusion. Biopsy confirmed retroperitoneal fibrosis with histological findings of IgG4-associated disease. Treatment with prednizone was poorly tolerated. Therefore, the patient was switched to the combination of rituximab 375 mg/m² on day 1, cyclophosphamide 300 mg/m² in infusion in days 1 and 15, plus dexamethasone 20 mg in infusion on days 1 and 15, repeated in a 28-day cycle. Results: Fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) examination after 4 months of treatment showed a marked decrease in FDG accumulation and complete disappearance of the fibrotic mass. After 8 months, the induction therapy was followed by maintenance therapy with rituximab 1,000 mg plus dexamethasone 20 mg in 6-month intervals. Control PET/MR examination after 3 years is consistent with complete remission. The number of circulating plasmablasts correlated with the disease activity. Conclusion: Treatment of retroperitoneal fibrosis with the tripple combination of rituximab, cyclophosphamide and dexamethasone achieved a very rapid disappearance of pathological FDG accumulation and fibrotic retroperitoneal mass, with complete disappearance achieved after 4 months of treatment. After 3 years of maitenance therapy, the diesease is still in complete remission on PET/MR examination. We suggest to continue the maintenance therapy with rituximab because of some increase in the number of circulating plasmablasts after prolongation of the intervals between rituximab administration.

Keywords:

Cyclophosphamide – rituximab – IgG4-related disease – retroperitoneal fibrosis – circulating plasmablasts

Zdroje

1. McDermott MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97 (1): 133–144. doi: 10.1016/S0092-8674 (00) 80721-7.

2. Betrains A, Staels F, Schrijvers R et al. Systemic autoinflammatory disease in adults. Autoimmun Rev 2021; 20 (4): 102774. doi: 10.1016/j.autrev.2021.102774.

3. Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process. J Urol 1948; 59 (6): 1072–1107. doi: 10.1016/S0022-5347 (17) 69482-5.

4. Raglianti V, Rossi GM, Vaglio A. Idiopathic retroperitoneal fibrosis: an update for nephrologists. Nephrol Dial Transplant 2021; 36 (10): 1773–1781. doi: 10.1093/ndt/gfaa083.

5. Laco J, Podhola M, Kamarádová K et al. Idiopathic vs. secondary retroperitoneal fibrosis: a clinicopathological study of 12 cases, with emphasis to possible relationship to IgG4-related disease. Virchows Arch 2013; 463 (5): 721–730. doi: 10.1007/s00428-013-1480-7.

6. Průcha M, Kolombo I, Štádler P. Ormond‘s disease – IgG4-related disease. Prague Med Rep 2015; 116 (3): 181–192. doi: 10.14712/23362936.2015.57.

7. Němec P, Rybníčková S, Fabián P et al. Idiopathic retroperitoneal fibrosis: an unusual cause of low back pain. Clin Rheumatol 2008; 27 (3): 381–384. doi: 10.1007/s10067-007-0736-5.

8. Němec P, Rybníčková S, Fabian P et al. Idiopatická retroperitoneální fibróza: méně častá příčina bolestí dolní části zad. Použití tamoxifenu v terapii onemocnění. Ces Revmatol 2008; 16 (1): 23–29.

9. Fedorko M, Krhovský M. Perirenální retroperitoneální fibróza. Urol Pro Praxi 2009; 10 (5): 299–301.

10. Kašík J, Kolombo I, Porš J et al. Primární retroperitoneální fibróza – morbus Ormond. Urol Pro Praxi 2008; 9 (3): 128–132.

11. Sobotka R, Hanuš T. Primární retroperitoneální fibróza. Urol Pro Praxi 2006; 7 (4): 156–159.

12. Pulcer J, Staněk R, Kokoř T et al. Fokální Ormondova choroba (idiopatická retroperitoneální fibróza). Urol Pro Praxi 2015; 16 (Suppl A): 30–31.

13. Chovancová Z, Filipenský P, Rotnáglová S et al. IgG4 immunoglobulin subclass and related pathological conditions or how to effectively imitate cancer disease. Klin Onkol 2022; 35 (1): 20–31.

14. Deshpande V, Zen Y, Chan JK et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012; 25 (9): 1181–1192. doi: 10.1038/modpathol.2012.72.

15. Wallace ZS, Naden RP, Chari S et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 2020; 79 (1): 77–87. doi: 10.1136/annrheumdis-2019-216561.

16. Wallace ZS, Naden RP, Chari S et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Arthritis Rheumatol 2020; 72 (1): 7–19. doi: 10.1002/art.41120.

17. Mizushima I, Morikage N, Ito E et al. Validation of the diagnostic criteria for IgG4-related periaortitis/periarteritis and retroperitoneal fibrosis (IgG4PA/RPF) 2018, and proposal of a revised 2023 version for IgG4-related cardiovascular/retroperitoneal disease. Circ J 2024; doi: 10.1253/circj.CJ-24-0026.

18. Adam Z, Zeman D, Čermák A et al. IgG4-related disease. Clinical manifestation differential diagnosis and recent International Diagnostic Criteria for IgG4-related disease. Vnitr Lek 2022; 68 (5): E4–E19. doi: 10.36290/vnl.2022.070.

19. Adam Z, Pour L, Zeman D. Vzácné choroby provázené hypergamaglobulinemií a zánětlivými projevy. Praha: Grada 2022.

20. Marvisi C, Accorsi Buttini E, Vaglio A. Aortitis and periaortitis: the puzzling spectrum of inflammatory aortic diseases. Presse Med 2020; 49 (1): 104018. doi: 10.1016/j.lpm.2020.104018.

21. Nikiphorou E, Galloway J, Fragoulis GE. Overview of IgG4-related aortitis and periaortitis. A decade since their first description. Autoimmun Rev 2020; 19 (12): 102694. doi: 10.1016/j.autrev.2020.102694.

22. Palmisano A, Urban ML, Corradi D et al. Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis? Rheumatology 2015; 54 (11): 2004–2009. doi: 10.1093/rheumatology/kev225.

23. Martorana D, Marquez A, Carmona FD et al. A large--scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis. J Allergy Clin Immunol 2018; 142 (5): 1662–1665. doi: 10.1016/j.jaci.2018.06.045.

24. Rossi GM, Rocco R, Accorsi Buttini E et al. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease. Intern Emerg Med 2017; 12 (3): 287–299. doi: 10.1007/s11739-016-1599-z.

25. Kučera M. Lokalizované fibrotické procesy. Ref Vyb Revmatol 1999; 39 (1): 36–40.

26. Kučera M, Kratochvíl P. Lokalizované fibrotické procesy (onemocnění), léčebné možnosti. Ref Vyb Revmatol 2000; 40 (4): 273–277.

27. Hermanová M. Idiopathic retroperitoneal fibrosis. Vnitr Lek 2011; 57 (5): 439–440.

28. Michaligová A, Plank L, Ježíková A et al. Morbus Ormond (idiopatic retroperitoneal fibrosis). Vnitr Lek 2011; 57 (5): 511–515.

29. Cronin CG, Lohan DG, Blake MA et al. Retroperitoneal fibrosis: a review of clinical features and imaging findings. AJR Am J Roentgenol 2008; 191 (2): 423–431. doi: 10.2214/AJR.07.3629.

30. Mizushima I, Kawano M. Renal involvement in retroperitoneal fibrosis: prevalence, impact and management challenges. Int J Nephrol Renovasc Dis 2021; 14: 279–289. doi: 10.2147/IJNRD.S239160.

31. Švihra J, Študent V. Retroperitoneálna fibróza. Urol Pro Praxi 2016; 17 (1): 14–16.

32. Wang H, Wang C, Wan Q et al. Roles of IgG4 and IgG4/IgG ratio to IgG4-related disease in patients with elevated serum IgG4 level. Clin Rheumatol 2023; 42 (3): 793–800. doi: 10.1007/s10067-022-06413-7.

33. Dítě Z, Novotný I, Kala Z et al. Pozitivita imunoglobulinu IgG4 v krevním séru u osob s karcinomem slinivky břišní. Gastroent Hepatol 2012; 66 (3): 187–190.

34. Slavíčková J, Lašťovička J. Elevace sérového imunoglobulinu G4 a diagnostika IgG4-asociované nemoci. Alergie 2018; 20 (2): 98–102.

35. van der Gugten G, DeMarco ML, Chen LYC et al. Resolution of spurious immunonephelometric IgG subclass measurement discrepancies by LC-MS/MS. Clin Chem 2018; 64 (4): 735–742. doi: 10.1373/clinchem.2017.282319.

36. Kawa S, Skold M, Ramsden DB et al. Serum IgG4 concentration in IgG4-related disease. Clin Lab 2017; 63 (9): 1323–1337. doi: 10.7754/Clin.Lab.2017.170403.

37. Wallace ZS, Mattoo H, Carruthers M et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis 2015; 74 (1): 190–195. doi: 10.1136/annrheumdis-2014-205233.

38. Lanzillotta M, Della-Torre E, Stone JH. Roles of plasmablasts and B cells in IgG4-related disease: implications for therapy and early treatment outcomes. Curr Top Microbiol Immunol 2017; 401: 85–92. doi: 10.1007/82_2016_58.

39. Wang Y, Zhao Z, Gao D et al. Clinical value of plasmablasts in predicting disease relapse in patients with IgG4-related disease. Clin Rheumatol 2023; 42 (1): 135–143. doi: 10.1007/s10067-022-06339-0.

40. Mattoo H, Mahajan VS, Della-Torre E et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. J Allergy Clin Immunol 2014; 134 (3): 679–687. doi: 10.1016/j.jaci.2014.03.034.

41. Lin W, Zhang P, Chen H et al. Circulating plasmablasts/plasma cells: a potential biomarker for IgG4-related disease. Arthritis Res Ther 2017; 19 (1): 25. doi: 10.1186/s13075-017-1231-2.

42. Kamburova EG, Koenen HJ, Borgman KJ et al. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant 2013; 13 (6): 1503–1511. doi: 10.1111/ajt.12220.

43. Wallace ZS, Deshpande V, Mattoo H et al. IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol 2015; 67 (9): 2466–2475. doi: 10.1002/art.39205.

44. Berti A, Della-Torre E, Gallivanone F et al. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. Rheumatology 2017; 56 (12): 2084–2092. doi: 10.1093/rheumatology/kex234.

45. Kermani TA, Crowson CS, Achenbach SJ et al. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc 2011; 86 (4): 297–303. doi: 10.4065/mcp.2010. 0663.

46. Scheel PJ Jr, Feeley N. Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation. Medicine 2009; 88 (4): 202–207. doi: 10.1097/MD.0b013e3181 afc439.

47. van Bommel EF, Jansen I, Hendriksz TR et al. Idiopathic retroperitoneal fibrosis: prospective evaluation of incidence and clinicoradiologic presentation. Medicine 2009; 88 (4): 193–201. doi: 10.1097/MD.0b013e3181afc420.

48. Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol 2016; 27 (7): 1880–1889. doi: 10.1681/ASN.2015101110.

49. van Bommel EF, Siemes C, Hak LE et al. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 2007; 49 (5): 615–625. doi: 10.1053/j.ajkd.2007.02.268.

50. Mizushima I, Inoue D, Yamamoto M et al. Clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis and periarteritis: a retrospective multicenter study. Arthritis Res Ther 2014; 16 (4): R156. doi: 10.1186/ar4671.

51. Adam Z, Čermák A, Petrášová H et al. Successful therapy of retroperitoneal fibrosis due to IgG4-related disease with rituximab, cyclophosphamide and glucocorticoids followed by maintenance therapy wit ritutixmab. Vnitr Lek 2023; 69 (3): E4–E15. doi: 10.36290/vnl. 2023.035.

52. Adam Z, Dastych M, Čermák A et al. Therapy of immunoglonuline IgG4 related disease (IgG4-RD). Vnitr Lek 2022; 68 (6): E15–E22. doi: 10.36290/vnl.2022.086.

53. Adam Z, Pour L, Štork M et al. Onemocnění asociované s imunoglobulinem IgG4 – klinické projevy a léčba. Farmakoterapie 2021; 17 (3): 448–458.

54. Maritati F, Corradi D, Versari A et al. Rituximab therapy for chronic periaortitis. Ann Rheum Dis 2012; 71 (7): 1262–1264. doi: 10.1136/annrheumdis-2011- 201166.

55. Almeqdadi M, Al-Dulaimi M, Perepletchikov A et al. Rituximab for retroperitoneal fibrosis due to IgG4-related disease: a case report and literature review. Clin Nephrol Case Stud 2018; 6: 4–10. doi: 10.5414/CNCS109321.

56. Carruthers MN, Topazian MD, Khosroshahi A et al. Rituximab for IgG4-related disease: a prospective, open--label trial. Ann Rheum Dis 2015; 74 (6): 1171–1177. doi: 10.1136/annrheumdis-2014-206605.

57. Dedinská I, Svetlík D, Adamicova K et al. Treatment of Ormond disease and idiopathic membranous glomerulonephritis by using rituximab. Iran J Kidney Dis 2016; 10 (5): 332–335.

58. Hamdan A, Moeen Z, Tariq H et al. An interesting case of immunoglobulin G4-related retroperitoneal fibrosis treated with rituximab. Cureus 2021; 13 (9): e17940. doi: 10.7759/cureus.17940.

59. Wallwork R, Wallace Z, Perugino C et al. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine 2018; 97 (42): e12631. doi: 10.1097/MD.0000000000012631.

60. Boyeva V, Alabsi H, Seidman MA et al. Use of rituximab in idiopathic; retroperitoneal fibrosis. BMC Rheumatol 2020; 4: 40. doi: 10.1186/s41927-020-00140-9.

61. Urban ML, Maritati F, Palmisano A et al. Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients. Ann Rheum Dis 2020; 79 (3): 433–434. doi: 10.1136/annrheumdis-2019-216258.

62. Ebbo M, Grados A, Samson M et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One 2017; 12 (9): e0183844. doi: 10.1371/journal.pone.0183844.44.

63. Oztas M, Altun I, Ayla AY et al. Rituximab in the management of retroperitoneal fibrosis: a single tertiary rheumatology care center experience. Int J Rheum Dis 2023; 26 (9): 1714–1721. doi: 10.1111/1756-185X.14798.

64. Fenaroli P, Maritati F, Vaglio A. Into clinical practice: diagnosis and therapy of retroperitoneal fibrosis. Curr Rheumatol Rep 2021; 23 (3): 18. doi: 10.1007/s11926-020-00966-9.

65. Dattani R, Barwick TD, El Wardany G et al. An international patient-centred study of retroperitoneal fibrosis. QJM 2022; 115 (3): 148–154. doi: 10.1093/qjmed/hcaa327.

66. Chellappan A, Bhawane A, Sharma A et al. IgG4-related kidney disease: a diagnostic conundrum successfully treated with steroids and rituximab. Cureus 2024; 16 (1): e52000. doi: 10.7759/cureus.52000.

67. Adam Z, Pour L, Zeman D et al. Obinutuzumab a bendamustin dosáhly u pěti pacientů s Waldenströmovou makroglobulinemií hlubší léčebné odpovědi než předchozí linie léčby. Acta Med 2023; 12 (5–7): 58–61.

68. Hanazono A, Sanpei Y, Shimada H et al. Remission of idiopathic retroperitoneal fibrosis by ofatumumab as a disease-modifying therapy for multiple sclerosis. eNeurologicalSci 2022; 29: 100428. doi: 10.1016/j.ensci.2022.100428.

69. Benucci M, Damiani A, Li Gobbi F et al. Jaccoud‘s arthropathy, an unusual manifestation of idiopathic retroperitoneal fibrosis: rapid improvement of symptoms after tocilizumab treatment. Reumatismo 2017; 69 (2): 88–91. doi: 10.4081/reumatismo.2017.968.

70. Perrotta FM, Fici M, Guerra G et al. Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report. Clin Exp Rheumatol 2017; 35 Suppl 103 (1): 226–227.

71. Vaglio A, Catanoso MG, Spaggiari L et al. Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum 2013; 65 (9): 2469–2475. doi: 10.1002/art.38032.

72. Loricera J, Blanco R, Castaeda S et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review. Clin Exp Rheumatol 2014; 32 (3 Suppl 82): S79–89.

73. Catanoso MG, Spaggiari L, Magnani L et al. Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol 2012; 30 (5): 776–778.

74. Gao H, Liu S, Mai Y et al. Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis. Ann Rheum Dis 2023; 82 (5): 688–697. doi: 10.1136/ard-2022-223736.

75. Campochiaro C, Della-Torre E, Lanzillotta M et al. Long--term efficacy of maintenance therapy with Rituximab for IgG4-related disease. Eur J Intern Med 2020; 74: 92–98. doi: 10.1016/j.ejim.2019.12.029.

76. Binder M, Uhl M, Wiech T et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 2012; 71 (2): 311–312. doi: 10.1136/annrheumdis-2011-200148.

77. Kohler HP, Laeng RH, Egger C et al. Systemic fibrosis (generalized form of Ormond’s disease). Report of a case which achieved complete remission with cyclophosphamide and corticosteroids. Schweiz Med Wochenschr 1995; 125 (44): 2131–2136.

78. Colomer Rubio E, Blanes Gallego A, Carbonell Biot C et al. Mesenteric panniculitis with retroperitoneal involvement resolved after treatment with intravenous cyclophosphamide pulses. An Med Interna 2003; 20 (1): 31–33.

79. Fotiou D, Theodorakakou F, Kastritis E. Monoclonal antibody-based therapies for Waldenström‘s macroglobulinemia. Leuk Res Rep 2022; 17: 100324. doi: 10.1016/j.lrr.2022.100324.

80. Adam Z, Pour L, Zeman D et al. Waldenström’s macroglobulinemia – clinical symptoms and review of therapy yesterday, today and tomorrow. Klin Onkol 2023; 36 (3): 177–191. doi: 10.48095/ccko2023177.

81. Adam Z, Zeman D, Chodacki A et al. et al. Therapy of Castleman’s disease with siltuximab – case report and review of literature. Klin Onkol 2023; 36 (4): 320–329.

82. Adam Z, Szturz P, Krejčí M et al. Treatment of 14 cases of Castlemans disease: the experience of one centre and an overview of literature. Vnitr Lek 2016; 62 (4): 287–298.

83. Adam Z, Řehák Z, Adamová Z et al. Multicentric Castlemans disease. Symptoms, diagnostics and therapy. Vnitr Lek 2022; 68 (1): 41–53.

84. Adam Z, Chovancová Z, Nová M et al. Remisson of the disease associated/related with immunoglobulin IgG4 accompanied by multiple lymphadenopathy after treatment with rituximab and dexamethasone: a case report. Vnitr Lek 2018; 64 (3): 290–299.

85. Löhr JM, Beuers U, Vujasinovic M et al. European Guideline on IgG4-related digestive disease – UEG and SGF evidence-based recommendations. United European Gastroenterol J 2020; 8 (6): 637–666. doi: 10.1177/2050640620934911.

86. On W, Huggett MT. European Guideline on IgG4--related digestive disease: UEG and SGF evidence--based recommendations. Frontline Gastroenterol 2021; 13 (2): 171–174. doi: 10.1136/flgastro-2021-101 884.

87. Němec P, Řehák Z, Fabián P et al. The use of positron emission tomography (18F-FDG PET) in diag- nosing chronic periaortitis. Vnitr Lek 2008; 54 (11): 1093–1099.

88. Tatoglu MT, Uslu H, Ibisoglu E. The value of (18) F-FDG PET/CT in diagnosis and evaluation of response to treatment in retroperitoneal fibrosis. Nuklearmedizin 2021; 60 (5): 381–382. doi: 10.1055/a-1429-2237.